Studieoverzicht

Study name: A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors

Histology	NSCLC, only squamous
Tumor stage	Stage III - IV
NCT Id	NCT05958121
Host / recruiting site 1	Antoni van Leeuwenhoek	Enrollment	Recruiting
Therapy line	Later line (≥2L)
Design	The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: To determine the maximum tolerated doses and/or recommended doses for extensions for IMA402 as monotherapy and in combination with pembrolizumab (Phase Ia) To characterize the safety and tolerability of IMA402 as monotherapy and in combination (Phase I/II) To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II) Secondary objectives: To evaluate the initial anti-tumor activity of IMA402 as monotherapy and in combination (Phase I) To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II) To describe the PK of IMA402 as monotherapy and in combination (Phase I/II)
Intervention	DRUG: IMA402 IV infusions DRUG: IMA402 and checkpoint inhibitor IMA402 IV infusions and checkpoint inhibitor DRUG: IMA402 and chemotherapy IMA402 IV infusions and chemotherapy DRUG: IMA402 and IMA401 IMA402 and IMA401 IV infusions DRUG: IMA402 and monoclonal antibody IMA402 IV infusions and monoclonal antibody DRUG: IMA402 and chemotherapy +/- monoclonal antibody IMA402 IV infusions and chemotherapy +/- monoclonal antibody
Key inclusion criteria	Patients ≥ 18 years old Patients must have a specific pathologically confirmed and documented advanced and/or metastatic solid tumor indication Patients must have received or not be eligible for indicated standard-of-care treatments per cohort Measurable disease according to RECIST 1.1 Confirmed HLA status ECOG Performance Status of 0 to 1 Adequate baseline hematologic, hepatic and renal function, acceptable coagulation status
Key exclusion criteria	Other active malignancies that require treatment or that might interfere with the trial endpoints The patient is pregnant or is breastfeeding History of hypersensitivity to components of IMA402 or rescue medications; hypersensitivity to or contraindication according to current SmPC for respective combination medicinal product The patient has concurrent severe and/or uncontrolled medical disease. Any other health condition that would, in the investigator's or sponsor's judgement, contraindicate the patient's participation in the clinical trial because of safety concerns or compliance with clinical trial procedures Patients with active brain metastases, history of bleeding into brain metastases, known brain metastases who are receiving therapeutic anticoagulation
Contact information	Log in voor de contactinformatie